snakebite deaths – Snakebites kill about 100,000 people a year worldwide, but for years the true toll was hidden by underreporting—especially in India. Antivenoms exist, yet costs, limited supplies in rural clinics, and mismatches between venom types and treatments have left man
For decades, the scale of snakebite death was treated like a mystery that couldn’t be measured. In India, official records long listed only about 1,000 snakebite deaths a year. Villages and farms tell a different story—people die at home. on the way to hospitals. and sometimes before anyone can even file a report.
Researchers using household death surveys and verbal autopsies have estimated that the real number in India alone is close to 60,000 a year. That gap between what was counted and what was happening helps explain why snakebites are still so deadly even though antivenoms exist.
The problem begins with biology. Snake venom differs from one snake species to the next. The mixes of toxins can attack the nervous system, muscles, or tissue in different ways. Antivenoms often have to be matched to the snakes found in a given region. An antivenom made for one set of snakes may do little against another.
Then comes the practical barrier that decides whether a treatment works at all: time. A person has to recognize the danger. reach a hospital or clinic in time. and—crucially—find a clinic with the appropriate antivenom in stock. In poor. rural communities. multiple steps can fail at once: getting to care. affording care. and even knowing exactly which snake delivered the venom.
There’s also money behind the logistics. Antivenoms are expensive to produce and buy. and they are hard to keep reliably stocked in the rural clinics where they’re needed most. And with deaths concentrated among people least able to pay, the market for better snakebite treatments has never been strong. In fact, in the last two decades, the market has gotten worse, with some manufacturers leaving the field altogether.
That economic reality became unmistakable in 2014, when Sanofi stopped producing Fav-Afrique, a vital antivenom for sub-Saharan Africa. The treatment neutralizes venom from 10 of the most dangerous snakes in the region. Sanofi halted production because it wasn’t profitable enough—an illustration of how snakebite can kill at enormous scale while targeting communities with little purchasing power.
The United States isn’t where snakebite typically dominates public fear. Sharks occupy the cultural imagination. But worldwide. snakes are among the deadliest animals: they kill about 100. 000 people a year. after mosquitoes and humans who “just murder each other. ” according to the framing of this reporting. In Australia. where many of the world’s most venomous snakes live. only about two people die from snakebites each year.
For years, the difference wasn’t just about venom. It was about whether deaths were visible enough to spur action—and whether treatments could actually reach patients.
In February. the World Health Organization issued its first formal blueprint for what next-generation snakebite drugs should look like. including treatments that could be given to victims before they reach a hospital. In 2024. after years of severe undercounting. India’s health ministry moved to make snakebite a notifiable disease. meaning every case and death has to be reported to public health authorities. and launched a national plan to bring those deaths down.
José María Gutiérrez. one of the field’s leading authorities on antivenom at the University of Costa Rica. wrote in an email that the field is “witnessing important developments (not sufficient. but important) on various fronts.” He also raised a tougher question: whether progress reaches the villages where most snakebite deaths happen.
Gutiérrez’s view is grounded in a long history of a stubborn challenge. The basic technology behind antivenoms dates back to the 1890s. when scientists figured out they could inject small amounts of snake venom into animals—usually horses and sheep—then harvest the antibodies their immune systems produced. Modern antivenoms are more carefully purified, processed, and quality-controlled, making them far safer and more effective than earlier versions.
But the core constraint remains: antibodies have to be matched to specific toxins, and making them at scale is still expensive.
That’s why new work is shifting away from a single solution. Scientists are now running human trials on snakebite treatments other than antivenom. including drugs that may not require cold storage or precise species matching. Tim Reed. who runs the Amsterdam-based NGO Health Action International. has argued that snakebite research and funders have leaned too heavily on expensive scientific solutions while community needs go unmet.
The promise of the drug pipeline is real, even if it doesn’t guarantee help soon enough. The most advanced new candidate is called varespladib. a drug that can be given as a pill that blocks one of the most damaging families of enzymes in snake venom. In a phase 2 trial, it appeared safe but did not clearly outperform standard care. Researchers now see it more as a field aid.
Other efforts are repurposing existing drugs and testing them against snakebites. including marimastat. a cancer drug. and DMPS. a drug used to treat heavy metal poisoning. Gutiérrez says these repurposed drugs are the most promising near-term options because researchers don’t have to start from zero; they have already been tested for other diseases. which means they can move into snakebite trials much faster than brand new drugs.
Clinical trials of some repurposed drugs are now underway in the US, India, and Kenya. Further out, researchers are working on new antibody therapies and AI-designed proteins targeted at specific snake toxins.
Still, even this excitement carries a warning: Reed says the pipeline has yet to bring anything to market. Hundreds of thousands of people have died from snakebite in recent years. and many more have been left with life-changing injuries. “with a disproportionate representation of children. ” Reed said.
When new drugs arrive, Reed worries, affordability may determine who benefits. The new treatments may eventually reach market, but they may still be priced out of reach for rural patients. He points to the fact that even varespladib is being brought forward by a small biotech company that will eventually need to recoup its investment—raising a practical question that matters as much as trial results: whether it will be affordable for a farmer in Bihar or western Kenya.
Reed also argues the global snakebite world still underfunds work that can help people now: prevention. first response. and community education. His organization has kept a small snakebite program going with its own funds. supporting school-based prevention work in Kenya and research in Rwanda. Its Women Champions of Snakebite network is still active. and it has helped launch a Snakebite Community Engagement Network run by people in the Global South.
These programs are small, but they’re built around the communities where snakebite actually happens.
A better response. Reed argues. has to do both at once—develop better drugs and fund the community work that can prevent snakebites and deaths now. “There’s been real progress, more so in some areas of concern than others,” Gutiérrez said. But, he added, “there is still a long road to go to give this problem the attention it deserves.”.
snakebite India antivenom World Health Organization public health reporting rural clinics varespladib marimastat DMPS Fav-Afrique Health Action International Jose Maria Gutierrez